How do you think about sequencing therapy for a patient with ALK+ metastatic NSCLC given the available options?   

The types and incidence of resistance mutations vary based on the 2nd generation ALK inhibitor given, and is most commonly the G1202R mutation, which unfortunately denotes resistance to alectinib where it accounts for about 29% of acquired resistance and brigatinib where it accounts for about 43% of...

Given the CNS-related and other adverse events that may be encountered with lorlatinib, its adoption as first-line therapy may not be as universally accepted (in contrast to experience with EGFR TKIs), given that the CROWN study compared 1st line therapy with crizotinib which is an outdated approach...

We have come a long way since the development and approval of crizotinib for ALK rearranged lung cancer. More recently, second generation ALK directed therapy including alectinib, brigatinib as well as ceritinib and ensartinib have been clinically tested and have shown improvement in outcome. More r...